Evidence map›Paper›PMID 33584653›Full record

ArticleFrontiers in immunology2020

Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15

Bella Guerrouahen, Muhammad Elnaggar, Anjud Al-Mohannadi, Dhanya Kizhakayil, Chiara Bonini, Reuben Benjamin, Renier Brentjens, Christian J Buchholz, Giulia Casorati, Soldano Ferrone and 8 more

Open access · goldAbstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 6 countries.

Bella GuerrouahenResearch Department, Sidra Medicine, Doha, Qatar.
Muhammad ElnaggarResearch Department, Sidra Medicine, Doha, Qatar.
Anjud Al-MohannadiResearch Department, Sidra Medicine, Doha, Qatar.
Dhanya KizhakayilResearch Department, Sidra Medicine, Doha, Qatar.
Chiara BoniniExperimental Hematology Unit, University Vita-Salute San Raffaele and Hospital San Raffaele Scientific Institute, Milan, Italy.
Reuben BenjaminDivision of Cancer Studies, King's College Hospital, London, United Kingdom.
Renier BrentjensCellular Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Christian J BuchholzResearch Unit for Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany.
Giulia CasoratiExperimental Immunology Unit, University Vita-Salute San Raffaele and Hospital San Raffaele Scientific Institute, Milan, Italy.
Soldano FerroneDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Frederick L LockeDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, United States.
Francisco MartinPfizer/University of Granada/Andalusian Regional Government, Genomic Medicine Department, Granada, Spain.
Axel SchambachInstitute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Cameron TurtleClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Paul VeysBone Marrow Transplant Unit, Great Ormond Street (GOS) Hospital, and University College London GOS Institute of Child Health, London, United Kingdom.
Hans J van der VlietHans van Der Vliet, Department of Medical Oncology, Amsterdam UMC, VU University and Cancer Center, Amsterdam, Netherlands.
Cristina MaccalliResearch Department, Sidra Medicine, Doha, Qatar.
EICCI Faculty Group
Harvard University · USVita-Salute San Raffaele University · ITAmsterdam University Medical Centers · NLFred Hutch Cancer Center · USGreat Ormond Street Hospital · GBKing's College Hospital · GBMemorial Sloan Kettering Cancer Center · USMoffitt Cancer Center · USPaul Ehrlich Institut · DEPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ES

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

The progress in the isolation and characterization of tumor antigen (TA)-specific T lymphocytes and in the genetic modification of immune cells allowed the clinical development of adoptive cell therapy (ACT). Several clinical studies highlighted the striking clinical activity of T cells engineered to express either Chimeric Antigen (CAR) or T Cell (TCR) Receptors to target molecularly defined antigens expressed on tumor cells. The breakthrough of immunotherapy is represented by the approval of CAR-T cells specific for advanced or refractory CD19

Indexed as

ImmunotherapyAnimalsGenetic EngineeringHumansImmunotherapy, AdoptiveNeoplasmsQatarReceptors, Chimeric AntigenT-LymphocytesReceptors, Chimeric AntigencancerCAR-NK cellsCAR-T cellsclinical trialimmunotherapymonoclonal antibodyoff-the-shelf developmentTCR engineered lymphocytes

Identifiers

PMID33584653
PMCPMC7874217
OpenAlexW3119649935

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.